docs/_posts/C-K-Loan/2021-03-29-recognize_entities_posology_en.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icdo_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-28-drug_action_treatment_mapper_en_3_0.md
docs/_posts/aydinmyilmaz/2021-01-18-ner_radiology_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_directions_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_problem_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_proceduretest_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_date_clinical_en.md
docs/_posts/aydinmyilmaz/2021-01-20-ner_deid_augmented_en.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_biobert_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_ro_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_ca_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_gl_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-26-bert_token_classifier_ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_anatem_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc2gm_gene_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc4chemd_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_jnlpba_cellular_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_linnaeus_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_ncbi_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_it.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_judgement_en.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_preamble_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_it.md
docs/_posts/dcecchini/2021-01-29-ner_drugs_large_en.md
docs/_posts/dcecchini/2021-07-23-cantemist_scielowiki_es.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-14-disease_mentions_tweet_es_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-assertion_oncology_treatment_binary_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-ner_oncology_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_anatomy_general_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_demographics_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_diagnosis_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_test_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_therapy_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_tnm_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_unspecific_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_anatomy_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_biomarker_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/xusliebana/2021-01-29-deidentify_enriched_clinical_en.md
docs/_posts/C-K-Loan/2021-03-29-recognize_entities_posology_en.md
docs/_posts/Damla-Gurbaz/2022-03-22-bert_token_classifier_drug_development_trials_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-drug_brandname_ndc_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icd10cm_umls_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-26-icdo_snomed_mapper_en_3_0.md
docs/_posts/Damla-Gurbaz/2022-06-28-drug_action_treatment_mapper_en_3_0.md
docs/_posts/aydinmyilmaz/2021-01-18-ner_radiology_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_directions_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_problem_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_bodypart_proceduretest_en.md
docs/_posts/aydinmyilmaz/2021-01-18-re_date_clinical_en.md
docs/_posts/aydinmyilmaz/2021-01-20-ner_deid_augmented_en.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_bert_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_biobert_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-22-ner_living_species_roberta_pt_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_bert_ro_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_ca_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_fr_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_gl_3_0.md
docs/_posts/bunyamin-polat/2022-06-23-ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-26-bert_token_classifier_ner_living_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_es_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_it_3_0.md
docs/_posts/bunyamin-polat/2022-06-27-bert_token_classifier_ner_living_species_pt_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_anatem_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc2gm_gene_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc4chemd_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_chemicals_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_bc5cdr_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_jnlpba_cellular_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_linnaeus_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_ncbi_disease_en_3_0.md
docs/_posts/bunyamin-polat/2022-07-25-bert_token_classifier_ner_species_en_3_0.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-25-legclf_bert_swiss_judgements_it.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_judgement_en.md
docs/_posts/bunyamin-polat/2022-10-25-legner_indian_court_preamble_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_de.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_en.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_fr.md
docs/_posts/bunyamin-polat/2022-10-27-legclf_bert_swiss_judgements_it.md
docs/_posts/dcecchini/2021-01-29-ner_drugs_large_en.md
docs/_posts/dcecchini/2021-07-23-cantemist_scielowiki_es.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_disease_mentions_tweet_es_3_0.md
docs/_posts/gpirge/2022-07-28-bert_token_classifier_ner_pathogen_en_3_0.md
docs/_posts/gpirge/2022-08-11-bert_token_classifier_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_negation_uncertainty_es_3_0.md
docs/_posts/gpirge/2022-08-13-ner_pharmacology_es_3_0.md
docs/_posts/gpirge/2022-08-14-disease_mentions_tweet_es_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-assertion_oncology_treatment_binary_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-07-25-ner_oncology_wip_en_3_0.md
docs/_posts/mauro-nievoff/2022-09-26-re_oncology_size_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_biomarker_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_location_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_temporal_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_test_result_wip_en.md
docs/_posts/mauro-nievoff/2022-09-27-re_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-28-redl_oncology_size_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_biomarker_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_granular_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_location_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_temporal_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-29-redl_oncology_test_result_biobert_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_anatomy_general_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_demographics_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_diagnosis_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_test_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_therapy_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_tnm_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_unspecific_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-09-30-ner_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_test_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-assertion_oncology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_anatomy_granular_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_biomarker_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_posology_wip_en.md
docs/_posts/mauro-nievoff/2022-10-01-ner_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_demographic_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_family_history_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_problem_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_response_to_treatment_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_smoking_status_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_treatment_binary_wip_en.md
docs/_posts/mauro-nievoff/2022-10-11-assertion_oncology_wip_en.md
docs/_posts/xusliebana/2021-01-29-deidentify_enriched_clinical_en.md
